# A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension

Study · id `cardio:ct-nct07833098` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07833098](<https://clinicaltrials.gov/study/NCT07833098>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07833098

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 240 participants.

## Technical summary

Registry record NCT07833098. Randomized; quadruple masking; primary purpose treatment. Start 2026-09 (anticipated); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT07833098, source copy `cardio:ctgov-nct07833098-2026-09-22`, retrieved 2026-10-26)
- Planned start: 2026-09 (anticipated) (ClinicalTrials.gov record NCT07833098, source copy `cardio:ctgov-nct07833098-2026-09-22`, retrieved 2026-10-26)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT07833098, source copy `cardio:ctgov-nct07833098-2026-09-22`, retrieved 2026-10-26)
- Completion: 2028-02 (anticipated) (ClinicalTrials.gov record NCT07833098, source copy `cardio:ctgov-nct07833098-2026-09-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07833098, source copy `cardio:ctgov-nct07833098-2026-09-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07833098-2026-09-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
- Condition: Hypertension
- Condition: Resistant Hypertension
- Condition: Uncontrolled Hypertension
- Intervention (Drug): VB19055 Dose A QD
- Intervention (Drug): VB19055 Dose B QD
- Intervention (Drug): VB19055 Dose C QD
- Intervention (Drug): VB19055 placebo QD
- Lead sponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Resistant hypertension (`cardio:resistant-hypertension`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 66e41694037190f3950904c22c512ce3270e1fe1e320c1c8e2919f16c9e0f809
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
